Sangamo BioSciences Reports Third Quarter 2009 Financi... (al and administrative expenses were $2.7...)

Sangamo BioSciences Reports Third Quarter 2009 Financial Results

Date:11/4/2009

al and administrative expenses were $2.7 million for the third quarter of 2009, compared to $2.6 million for the same period in 2008. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash employee stock-based compensation, which totaled $0.9 million in the third quarter of 2009 compared to $0.7 million in the same period in 2008.

Total operating expenses for the third quarter of 2009 were $8.9 million, compared to $10.1 million for the same period in 2008.

Net interest and other income (loss) were recorded as a net loss of $47,000 for the third quarter of 2009 compared to income of $42,000 for the same period in 2008.

Nine Month Results

For the nine months ended September 30, 2009, the consolidated net loss was $16.2 million, or $0.39 per share, compared to a consolidated net loss of $21.7 million, or $0.53 per share, for the nine-months ended September 30, 2008. Revenues were $11.9 million for the nine months ended September 30, 2009, compared to $9.4 million for the same period in 2008. Total operating expenses were $28.9 million for the nine months ended September 30, 2009, compared to $32.5 million for the same period in 2008. The decrease in operating expenses for 2009 was primarily associated with decreased manufacturing, preclinical, consulting and lab supply expenses.

Recent Highlights

Presentation of top-line statistically significant Phase 2 ZFP Therapeutic(TM) data at the Society for Neuroscience Meeting. Sangamo presented top-line, statistically significant Phase 2 clinical data from its zinc finger DNA-binding protein (ZFP) Therapeutic program to develop SB-509 for treatment of diabetic neuropathy (DN) at the Society for Neuroscience Annual Meeting held in Chicago. The data demonstrated a direct neuroregenerative effect of SB-509 treatment that resulted in a statistically significant (p v
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
4. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
5. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
6. Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
7. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
8. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
9. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
10. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference

Post Your Comments:

Sangamo BioSciences Reports Third Quarter 2009 Financi...(al and administrative expenses were $2.7...),Health